Regeneron sues Sanofi over Dupixent commercialization discord
Feb 6, 2025 · In a lawsuit that received little attention toward the end of last year, Regeneron has taken Sanofi to court over claims that its marketing and development partner violated the …
Dupixent® (dupilumab) Approved as the First-ever Biologic …
Mar 28, 2025 · In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other …
Sanofi sheds Regeneron stake, but insists collaboration is unaffected
6 days ago · Sanofi holds a 20.6% stake in Regeneron, and has said it will shed around 12.8 million shares out of its current 23.2 million stake. Some will be sold via a public offering, with …
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
Sep 27, 2024 · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of …
Regeneron's Sanofi deal finally turns a profit, thanks to Dupixent
Aug 6, 2019 · More than 10 years after Sanofi and Regeneron joined forces in a high-profile antibody drug partnership, the tie-up has recorded its first-ever profits—no thanks to the …
Sanofi US News
Sep 27, 2024 · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled …
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
Feb 7, 2025 · Regeneron revealed in its annual SEC report on Wednesday that it has sued Sanofi, claiming that its Dupixent partner “breached certain provisions” of their agreement …
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30, 2024 · Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary …
Press Release: Sanofi grants Regeneron worldwide exclusive …
Jun 2, 2011 · Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo. The Sanofi and Regeneron global …
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous ...
Feb 18, 2025 · Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti …